Q-omics provides the consensus-scored KAT6A profile across patient tissues and cancer cell-line models. KAT6A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KAT6A is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, KAT6A RNA expression shows 20,905 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where KAT6A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KAT6A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KAT6A survival associations across molecular data types. KAT6A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KAT6A RNA expression–survival associations across cancer types. High KAT6A expression shows unfavorable associations in KICH and ACC, but favorable associations in KIRC, HNSC, BRCA and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KAT6A RNA expression.
This table summarizes KAT6A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for KAT6A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KAT6A shows lower tumor expression in THCA and higher tumor expression in STAD, CHOL, LIHC, READ and HNSC. The THCA box plot shows higher KAT6A RNA expression in normal versus tumor tissue (log2 FC = −0.636, t-test p < 0.001).
This table shows molecular features associated with KAT6A in patient tissues and cancer cell lines. In patient samples, KAT6A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KAT6A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
